The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

President Trump will continue to pursue the policy of Medicare pricing negotiation introduced by former President Biden's Inflation Reduction Act (IRA) but will look at refining the programme.

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

The price negotiation process was established under former President Joe Biden's signature Inflation Reduction Act in 2022.

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

On Friday, Novo Nordisk A/S NVO released topline results ... Also Read: Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations The primary endpoint was the treatment ...

The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

Minnesota Attorney General Keith Ellison says his office has reached a settlement with Novo Nordisk over high insulin ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...